Skip to main content
Guobang Pharma Ltd. logo

Guobang Pharma Ltd. — Investor Relations & Filings

Ticker · 605507 ISIN · CNE100004NS2 LEI · 300300PS6T4W4PGYPM51 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 510 across all filing types
Latest filing 2024-12-19 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 605507

About Guobang Pharma Ltd.

https://www.gbgcn.com

Guobang Pharma Ltd. specializes in the research, development, manufacture, and distribution of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and finished dosage forms. The company operates across two primary sectors: human health and animal health. Its product portfolio includes a wide range of anti-infectives, such as macrolides and quinolones, as well as cardiovascular medications and veterinary drugs like florfenicol. Guobang Pharma maintains a comprehensive industrial chain, leveraging large-scale production facilities and advanced chemical synthesis technologies to serve global markets. The organization focuses on providing integrated solutions for pharmaceutical raw materials, emphasizing quality control and regulatory compliance to meet international standards.

Recent filings

Filing Released Lang Actions
国邦医药关于全资子公司产品氟苯尼考通过美国FDA现场检查的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Guobang Pharmaceutical Group Co., Ltd. regarding the successful passing of a cGMP on-site inspection by the US FDA for its wholly-owned subsidiary's product. It details the inspection scope, results, and implications for the company. The document is relatively short (1122 characters) and serves as a regulatory announcement about compliance and inspection results rather than a full financial or operational report. It does not contain financial statements, management discussion, or detailed data. It is not a report publication announcement since it provides substantive information about the FDA inspection outcome. The content fits best under Regulatory Filings (RNS) as it is a compliance and regulatory update without fitting into other specific categories like Annual Report, Earnings Release, or Legal Proceedings.
2024-12-19 Chinese
国邦医药关于为子公司提供担保进展的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Guobang Pharmaceutical Group Co., Ltd. regarding the progress of guarantees provided for its subsidiary Zhejiang Qifangbei Beverage Co., Ltd. It details the guarantee amount, the internal decision-making process, the subsidiary's basic information, and the necessity and rationality of the guarantee. The document is a formal disclosure about a financial guarantee arrangement, including specifics about the guarantee contract and the company's overall guarantee exposure. It does not contain financial statements or comprehensive financial performance data, nor is it a report or presentation. It is a regulatory announcement about a capital/financing-related activity (providing guarantees for financing). Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is 2039 characters, which is short but contains substantive information about financing guarantees, not just a report publication announcement or a regulatory filing. Confidence is high due to clear content focus on guarantee financing update.
2024-12-08 Chinese
国邦医药关于以集中竞价交易方式回购股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Guobang Pharmaceutical Group Co., Ltd. regarding the progress of its share repurchase program through centralized bidding transactions. It details the number of shares repurchased, the price range, total amount spent, and compliance with relevant regulations. The document does not contain financial statements or detailed financial analysis but focuses on the update of the company's share buyback activity. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback or sale of its own shares.
2024-12-02 Chinese
国邦医药关于股东减持股份结果公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding the results of a shareholder's reduction in shareholding. It details the shareholders involved, the number of shares reduced, the percentage of total shares, the period of reduction, and the completion status of the reduction plan. There is no financial report, earnings data, or management discussion. The document is a formal disclosure of shareholding changes by significant shareholders, specifically about the completion of a share reduction plan. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels.
2024-11-29 Chinese
国邦医药关于以集中竞价交易方式回购股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Guobang Pharmaceutical Group Co., Ltd. regarding the progress of its share repurchase program through centralized bidding transactions. It details the number of shares repurchased, the price range, total amount spent, and the purpose of the repurchase (employee stock ownership plan or equity incentives). The document references regulatory rules on share repurchases and provides updates on the progress of the buyback. It does not contain financial statements or detailed financial analysis but is clearly an update on the company's share repurchase activity. Therefore, it fits the category of a Transaction in Own Shares (POS) filing, which covers reports of the company buying back or selling its own shares.
2024-11-01 Chinese
国邦医药关于召开2024年第三季度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2024 third quarter earnings explanation meeting (业绩说明会), including time, location, participation method, and contact information. It references the prior release of the 2024 Q3 report but does not contain any financial data or analysis itself. The document is short (1432 characters) and serves to inform investors about the upcoming earnings call event rather than presenting the earnings report or transcript. Therefore, it is best classified as an Investor Presentation (IP) type, as it focuses on the presentation and interaction with investors regarding financial results.
2024-10-22 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.